Page 10 - Read Online
P. 10
10 PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues
Pooja Murthy, Franco Muggia
Cancer Drug Resist 2019;2:665-679 http://dx.doi.org/10.20517/cdr.2019.002
11 Emerging targets in cancer drug resistance
Shashank Kumar, Prem Prakash Kushwaha, Sanjay Gupta
Cancer Drug Resist 2019;2:161-177 http://dx.doi.org/10.20517/cdr.2018.27
12 Insights into breast cancer phenotying through molecular omics approaches and therapy response
Jose E. Belizario, Angela F. Loggulo
Cancer Drug Resist 2019;2:527-538 http://dx.doi.org/10.20517/cdr.2018.009
13 Somatic pharmacogenomics of gastrointestinal stromal tumor
Gloria Ravegnini, Patrizia Hrelia, Sabrina Angelini
Cancer Drug Resist 2019;2:107-115 http://dx.doi.org/10.20517/cdr.2019.02
14 Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma
Marta Alonso-Peña, Anabel Sanchez-Martin, Paula Sanchon-Sanchez, Meraris Soto-Muñiz,
Ricardo Espinosa-Escudero, Jose J.G. Marin
Cancer Drug Resist 2019;2:680-709 http://dx.doi.org/10.20517/cdr.2019.006
